Jeffrey M. Bozarth - Concepedia

Concepedia

Author

Jeffrey M. Bozarth

Bristol-Myers Squibb (United States)

Also Known As

Bozarth, Jeffrey M., J M Bozarth, J. Bozarth, J.M. Bozarth, Jeffrey Bozarth, Jeffrey M Bozarth, Jeffrey M. Bozarth

47

Publications

1.1K

Citations

20

H-Index

36

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Wilmington University DuPont (United States)Bristol-Myers Squibb (India)Syngene International (India)

JM

About

Jeffrey M. Bozarth is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	541
2	Natural Sciences	9	9	245
3	Biochemistry	9	9	223
4	Biomolecular Engineering	3	3	93
5	Chemical Biology	1	1	20

Jeffrey M. Bozarth

×

29

Publications

1.1K

Citations

20

H-Index

	Year	Citations
Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Shaker A. Mousa, Jeffrey M. Bozarth, Mark S. Forsythe, Circulation	1994	103
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte, Journal of Medicinal Chemistry	2021	93
Design, Synthesis, and Evaluation of Radiolabeled Integrin α <sub> <i>v</i> </sub> β <sub>3</sub> Receptor Antagonists for Tumor Imaging and Radiotherapy Thomas D. Harris, Shirley Kalogeropoulos, Tiffany Nguyen, Cancer Biotherapy and Radiopharmaceuticals	2003	82
Tetrahydroquinoline Derivatives as Potent and Selective Factor XIa Inhibitors Mimi L. Quan, Pancras C. Wong, Cailan Wang, Journal of Medicinal Chemistry Rabbit Thrombosis ModelsPharmacotherapyPharmaceutical ChemistryThrombosisMedicinal Chemistry	2014	76
Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits Pancras C. Wong, Earl J. Crain, Jeffrey M. Bozarth, Journal of Thrombosis and Haemostasis ThrombosisDirect InhibitorBlood PlateletMedicineHematology	2021	58
Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban Shaker A. Mousa, Jeffrey M. Bozarth, Ulhas P. Naik, British Journal of Pharmacology Proteinlipid InteractionImmunologyMolecular BiologyRoxifiban Active FormPharmacotherapy	2001	50
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212) Donald Pinto, Michael J. Orwat, Leon M. Smith, Journal of Medicinal Chemistry	2017	50
Novel nonpeptide antiplatelet glycoprotein llb/llla receptor antagonist, DMP754 Shaker A. Mousa, Mark S. Forsythe, William Lorelli, Coronary Artery Disease	1996	47
Antiplatelet Efficacy of XV459, A Novel Nonpeptide Platelet GPIIb/IIIa Antagonist: Comparative Platelet Binding Profiles with c7E3 Shaker A. Mousa, Jeffrey M. Bozarth, William Lorelli, Journal of Pharmacology and Experimental Therapeutics	1998	41
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties Donald Pinto, Joanne M. Smallheer, James R. Corte, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryPharmaceutical ScienceNovel P1 MoietiesBiochemistryMedicine	2015	40

Page 1